The ten Phase 1 winners were recommended by the LymeX Diagnostics Prize judging panel. Each winner is awarded $100,000 and an exclusive invitation to participate in a planned Phase 2. In Phase 2, LymeX anticipates winners will prototype and refine their solutions with additional validation data and clinical protocol development.
A molecular diagnostic blood test for Lyme B. burgdorferi s.l. using innovative polymerase chain reaction (PCR) assay that targets biomarkers for increased accuracy using standard laboratory equipment.
A small-volume serum test using glycan biomarkers to detect active Lyme disease infection, track treatment response, and distinguish between diseases with similar symptoms.
A urine direct test that targets absolutely specific protein molecules and would provide direct information about pathogen activity.
A test combining novel sample preparation and artificial nucleic acid detection to identify active infection in whole blood, synovial fluid, and cerebrospinal fluid.
An automated, quantified, array-based serum test using machine learning to improve sensitivity in categorizing specimens.
A plasma test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.
A universal multiplex serum test that incorporates patient-centric surveillance testing, population data, and machine learning to enhance understanding of tick-borne diseases.
A whole blood test designed to directly detect Lyme disease-causing bacteria, providing results in three to five hours with higher accuracy.
A serum test targeting a unique antibody that would more accurately identify early infection and allow clinicians to optimize additional treatment.
A test using monoclonal antibodies in conjunction with immuno-PCR to detect a unique B. burgdorferi biomarker in multiple biofluids.